<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550910</url>
  </required_header>
  <id_info>
    <org_study_id>RO1912-30902</org_study_id>
    <nct_id>NCT04550910</nct_id>
  </id_info>
  <brief_title>RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients</brief_title>
  <acronym>Breastcancer</acronym>
  <official_title>Randomized Clinical Trial Comparing Two Adjuvant Radiotherapy Hypo Fractionation Schedules In The Treatment of Post Mastectomy Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy&#xD;
      hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in&#xD;
      5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with&#xD;
      breast cancer after mastectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      166 patients of breast cancer patients after mastectomy ( 83 patients in each arm ) will be&#xD;
      randomize into 2 hypofractionation arms : Arm A: 40 Gy /15 fx / 3 weeks, 5 days per week .&#xD;
      Arm B: 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week.&#xD;
&#xD;
      Simulation:&#xD;
&#xD;
      Patient will be simulated on CT simulator using breast wedge with angle. Serials will be&#xD;
      taken every 2 mm from upper neck down to mid abdomen.&#xD;
&#xD;
      Contouring:&#xD;
&#xD;
      CTVcw, CTVRNI will be contoured through RTOG guidelines . PTV is added as 0.5 cm all around&#xD;
      CTV. Lungs, Heart, brachial plexus, spinal cord, esophageus and thyroid will be contoured as&#xD;
      OAR. (www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx).&#xD;
&#xD;
      D)Dose Constraints:&#xD;
&#xD;
      Arm A:&#xD;
&#xD;
      PTV EVAL ( CW) : V90 % ≥ 90 %. - V105 % ≤ 5% - V107%≤ 3 %. Ipsilateral lung: V20 less than&#xD;
      20-25% - V 8 less than 35%- Contra lateral lung: V4 less 10 %. Heart: V16 less than 5% (Lt&#xD;
      sided). V20 less than 5% (Lt sided). V16 is 0%.(Rt sided) V20 is 0% (Rt sided). Mean heart&#xD;
      dose ≤ 320-400 cGy. Contra lateral breast : D max≤ 240 cGy. V 144 cGy less than 5 %. SCV :&#xD;
      V90 % ≥ 90 %. Thyroid : Mean dose less than 35 Gy - V30 less than 50 %.&#xD;
&#xD;
      Arm B:&#xD;
&#xD;
      PTV EVAL ( CW) : V90 %≥ 90 %. - V105 %≤ 5% - V107%≤ 2 %.&#xD;
&#xD;
      Ipsilateral lung: V30%less than 15 -20% - V15% less than 30-35% - V5 % less than 50-55%.&#xD;
&#xD;
      Contra lateral lung : V5 % less than 5%. Heart :V25 % less than 5 % - V5 % less than 30 - 35&#xD;
      %. Contra lateral breast: V3 % less than 5 %. SCV : V90 % ≥ 90 %.&#xD;
&#xD;
      Follow up:&#xD;
&#xD;
      A)Weekly follow up will be done during sessions then regular clinical exam every 3 months to&#xD;
      assess :&#xD;
&#xD;
        1. Acute and late toxicity regarding pain, pulmonary toxicity, dysphagia, skin toxicity and&#xD;
           lymphedema.Assessment will be done according to RTOG and CTCv.5.&#xD;
&#xD;
        2. Any local (chest wall) recurrence, regional (nodal) recurrence.&#xD;
&#xD;
      B)Annual Mammogram. C)Any another investigation (once indicated)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chest wall pain</measure>
    <time_frame>3 months form starting of Adjuvant radiotherapy to chest wall.</time_frame>
    <description>Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dysphagia</measure>
    <time_frame>3 months form starting Adj radiotherapy to chest wall.</time_frame>
    <description>Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin</measure>
    <time_frame>3 months form staring adjvant radiotherapy to chest wal.</time_frame>
    <description>Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Toxicity</measure>
    <time_frame>Assessment will be started 6 months after end of adjuvant radiotherapy to chest wall then Biannaully for 2 years.</time_frame>
    <description>Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial plexopathy</measure>
    <time_frame>Assessment will be started 6 months after end of adjuvant radiotherapy to chest wall then Biannaully for 2 years.</time_frame>
    <description>Grades of toxicity will be assessed according to The Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria. Scoring starts with low grade toxicity sacle ( Grade 1 or 2) while Grade 3 or 4 considered High grade toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphedema</measure>
    <time_frame>Assessment will be started 6 montha form ending adjuvant radiotherapy to chest wall and axilla then then Biannaully for 2 years.</time_frame>
    <description>Common Toxicity Criteria v.5 ( Arm volume at CC.Grading done according to Interlimb Volume Difference.Interlimb volume difference &gt; 30 % is considered Grade 3 Lymphedema) and Cheng scale ( To detect proportion of patients having moderate or severe lymphedema (Grade 》II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>Annually after the end of chest wall irradiation for 2 years. ] must be confirmed by cytological/ histological assessment</time_frame>
    <description>Local Recurrence Rate (LCR) including ipsilateral chest wall +/- regional nodal recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Locoregional Recurrence</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation Schedules for Breast Cancer patients after mastecomy</intervention_name>
    <description>Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invasive carcinoma of the breast.&#xD;
&#xD;
          -  Complete microscopic excision of primary tumour and axillary dissection or SLNB .&#xD;
&#xD;
          -  Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate&#xD;
             for neoadjvant chemotherapy regardless pathological stage after mastectomy.&#xD;
&#xD;
          -  Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront&#xD;
             mastectomy.&#xD;
&#xD;
          -  Able to comply with follow up.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients do not match with inclusion criteria.&#xD;
&#xD;
          -  Collagen vascular disease, specifically systemic lupus, or scleroderma.&#xD;
&#xD;
          -  Pregnancy or lactation at the time of radiotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Yousof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Momen Hassan, MSc.</last_name>
    <phone>+2001004209003</phone>
    <email>momen_onco@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Osama Yousof, MD</last_name>
    <phone>+20 122 775 2455</phone>
    <email>osama.soliman@nci.cu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NCIEGYPT</name>
      <address>
        <city>Cairo</city>
        <state>Fom Elkhalig</state>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Momen Hassan, MSc.</last_name>
      <phone>+201004209003</phone>
      <email>momen_onco@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.thegreenjournal.com/article/S0167-8140(11)00337-9/pdf</url>
    <description>First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015): The FAST Trial lists group. Radiotherapy and Oncology, 100(1), pp.93</description>
  </link>
  <link>
    <url>http://www.ascopost.com/News/59403</url>
    <description>FAST Trial Finds Long-Term Side Effects Similar for Once-Weekly and Conventional Breast Radiation Therapies</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Momen Elsayed Hassan, MSc.</investigator_full_name>
    <investigator_title>Assistant Lecturer of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Post Op radiotherapy</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Locoregional Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

